Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Common Equity: 2009-2022

Historic Common Equity for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Sep 2022 value amounting to -$12.4 million.

  • Avadel Pharmaceuticals' Common Equity fell 112.57% to -$12.4 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$12.4 million, marking a year-over-year decrease of 112.57%. This contributed to the annual value of $78.2 million for FY2021, which is 51.78% down from last year.
  • As of Q3 2022, Avadel Pharmaceuticals' Common Equity stood at -$12.4 million, which was down 273.35% from -$3.3 million recorded in Q2 2022.
  • Avadel Pharmaceuticals' Common Equity's 5-year high stood at $182.1 million during Q2 2020, with a 5-year trough of -$29.2 million in Q4 2019.
  • Its 3-year average for Common Equity is $92.7 million, with a median of $99.0 million in 2021.
  • Per our database at Business Quant, Avadel Pharmaceuticals' Common Equity plummeted by 1,150.32% in 2019 and then surged by 1,124.50% in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' Common Equity (Quarterly) stood at $2.8 million in 2018, then plummeted by 1,150.32% to -$29.2 million in 2019, then spiked by 655.72% to $162.3 million in 2020, then plummeted by 51.78% to $78.2 million in 2021, then tumbled by 112.57% to -$12.4 million in 2022.
  • Its Common Equity was -$12.4 million in Q3 2022, compared to -$3.3 million in Q2 2022 and $55.2 million in Q1 2022.